Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6.8% - What's Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price fell 6.8% on Tuesday . The stock traded as low as $25.04 and last traded at $25.21. 156,085 shares were traded during mid-day trading, a decline of 55% from the average session volume of 344,286 shares. The stock had previously closed at $27.04.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Oppenheimer raised their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, November 11th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a "buy" rating for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $46.43.

Dianthus Therapeutics Trading Down 5.3 %

The company has a market capitalization of $757.98 million, a PE ratio of -10.24 and a beta of 1.74. The business has a fifty day moving average of $24.65 and a 200 day moving average of $26.60.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after buying an additional 1,124 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Dianthus Therapeutics in the second quarter worth approximately $236,000. SG Americas Securities LLC grew its holdings in Dianthus Therapeutics by 104.0% during the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock worth $242,000 after acquiring an additional 4,506 shares in the last quarter. Fred Alger Management LLC grew its holdings in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock worth $264,000 after acquiring an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $265,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.